Topical Immunotherapy in Dermatology

Topical immunotherapy was used since the 1970s to treat skin conditions like extensive alopecia areata and resistant viral warts, which were thought to result from an altered immunological state. Despite its effectiveness, it was only offered by a few dermatology departments in the UK. Diphencyprone (DCP) was preferred over other contact sensitisers like dinitrochlorobenzene (DNCB) and squaric acid dibutyl ester (SADBE) due to its advantages. Careful handling of solutions was necessary to prevent sensitisation of medical staff. Common risks included local blistering and eczematous eruptions, while vitiligo and erythema multiforme-like reactions were rare. DCP with close supervision was considered a useful treatment option for severe alopecia areata and resistant viral warts.